Prospective Validation of Rapid Plasma Genotyping for the Detection of<i>EGFR</i>and<i>KRAS</i>Mutations in Advanced Lung Cancer
Adrian G. Sacher(Princess Margaret Cancer Centre), Geoffrey R. Oxnard(Foundation Medicine (United States)), Stacy L. Mach(Brigham and Women's Hospital), Pasi A. Jänne(Harvard University), Cloud P. Paweletz(Massachusetts General Hospital), Ryan S. Alden(AstraZeneca (Singapore)), Nora Feeney(Dana-Farber Cancer Institute), Allison O’Connell(Brigham and Women's Hospital), Suzanne E. Dahlberg(Dana-Farber Cancer Institute)
Cited by 567
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k